Astellas aims to create innovative pharmaceuticals for diseases with high unmet medical needs through our Focus Area approach. In the Focus Area approach, we prioritize our research and development strategy utilizing three perspectives: “biology”, which has clear mechanisms of pharmacological action with accompanying scientific progress, “modality”, which seeks the best delivery method to maximize pharmacological effects, and “disease”, which has undergone widespread evaluation of unmet medical needs and the market environment. To selected opportunities within the Focus Area where there is clear scientific evidence and the potential to create and deliver VALUE to patients, we allocate management resources to accelerate progress from the early development stages.

In the clinical development phase, Astellas prioritizes six key late stage projects and develops our products to maximize the contribution to addressing unmet medical needs in various diseases.